Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.
Measurement of complement components in serum may not accurately assess the degree of activation of the complement system. An alternative approach is the measurement of conversion products of the complement components. The relation between the presence of an increased concentration of C3-conversion products and the metabolism of C3 was investigated. In a group of patients, circulating immune complexes were also measured (Clq-binding test) to see whether the combination of those markers yielded information on the C3 metabolism. In this study it is shown that static measurements of serum C3 levels is of no value for the degree of complement activation. Measurement of C3-conversion products may indicate C3 hypercatabolism (in 8 of the 11 patients with C3-conversion products), but it does not imply depressed C3 synthesis. Detection of circulating immune complexes by the C1q-binding assay did not always indicate a C3 hypercatabolism. Of 12 SLE patients studied, in 9 of them, a C3 hypercatabolism was detected, and 5 of these patients were clinically characterized by the presence of minor disease symptoms. Overall, the results indicated that detection of circulating immune complexes and/or C3-conversion products could not be used as an absolute measure for insight into the C3 metabolism.
D000936:Antigen-Antibody Complex / Q000032:analysis*; D003176:Complement C3 / Q000032:analysis / Q000096:biosynthesis / Q000378:metabolism*; D003179:Complement C3b / Q000032:analysis; D015932:Complement C3c; D015933:Complement C3d; D006207:Half-Life; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000378:metabolism*
D000936:Antigen-Antibody Complex; D003176:Complement C3; D003179:Complement C3b; D015932:Complement C3c; D015933:Complement C3d